

# AstraZeneca

08:32 03 Apr 2018

## US and European regulators accept AstraZeneca's cancer drug applications

US and European regulators have accepted applications for AstraZeneca PLC's (LON:AZN) cancer treatments Moxetumomab Pasudotox and Lynparza .

AstraZeneca said the US Food and Drug Administration (FDA) has accepted the biologics license application for Moxetumomab Pasudotox, used to treat hairy-cell leukaemia in adults.

**READ:** AstraZeneca pushes back timeline for MYSTIC phase III lung cancer clinical trial

The FDA has also granted the medicine priority-review status.

The European Medicines Agency will review AstraZeneca's marketing authorisation application for Lynparza, representing the first regulatory submission for a poly ADP-ribose polymerase inhibitor for breast cancer in Europe.


Lynparza is used for patients who have metastatic breast cancer and have been treated with chemotherapy.

Shares in AstraZeneca fell 0.7% to 4,858p in morning trading.

**Price:** 7665

**Market Cap:** £99.85 billion

### 1 Year Share Price Graph



### Share Information

**Code:** AZN

**Listing:** LSE

**52 week High Low**  
72750 109.511

**Sector:** Pharma & Biotech

**Website:** [www.astrazeneca.com](http://www.astrazeneca.com)

### Company Synopsis:

*AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 employees and operates in over 100 countries with growing presence in important emerging markets.*

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability,

value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.